<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472014</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-03x</org_study_id>
    <nct_id>NCT03472014</nct_id>
  </id_info>
  <brief_title>Special Access Program IMVAMUNE®</brief_title>
  <official_title>A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of&#xD;
      replicating vaccinia virus&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2010</start_date>
  <completion_date type="Actual">November 14, 2014</completion_date>
  <primary_completion_date type="Actual">November 14, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ELISA Seropositivity Rate</measure>
    <time_frame>up to Week 7</time_frame>
    <description>Seropositivity rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seropositivity is defined as antibody titers ≥ detection limit (50). Percentages based on number of subjects with data available.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ELISA Seroconversion Rate</measure>
    <time_frame>Week 7</time_frame>
    <description>Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to the Screening titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMT</measure>
    <time_frame>up to Week 7</time_frame>
    <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Related Grade &gt;=3 Adverse Events</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Incidence of any Grade &gt;=3 Adverse Events possibly, probably or definitely related to the trial vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-serious AEs</measure>
    <time_frame>within 29 days after any vaccination</time_frame>
    <description>Incidence of non-serious AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Vaccination</condition>
  <arm_group>
    <arm_group_label>IMVAMUNE®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE®</intervention_name>
    <description>IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose</description>
    <arm_group_label>IMVAMUNE®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects, aged 18-65 years, who will work with or in the vicinity of a&#xD;
             replicating vaccinia virus and who volunteer for the program. Subjects may be&#xD;
             vaccinia-naïve or vaccinia-experienced.&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) must have a negative urine pregnancy test&#xD;
             within 48 hours prior to vaccination.&#xD;
&#xD;
          -  WOCBP must have used an acceptable method of contraception for at least 30 days prior&#xD;
             to the first vaccination and must agree to use an acceptable method of contraception&#xD;
             during the vaccination period until at least 28 days after the last vaccination. A&#xD;
             woman is considered of child-bearing potential unless post-menopausal or surgically&#xD;
             sterilized. (Acceptable contraception methods are restricted to barrier contraceptives&#xD;
             which include Food and Drug Administration (FDA)-approved spermicides, intrauterine&#xD;
             contraceptive devices, or licensed hormonal products.)&#xD;
&#xD;
          -  Read, signed and dated Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Uncontrolled serious infection i.e., not responding to antimicrobial therapy.&#xD;
&#xD;
          -  History of or active autoimmune disease. Persons with vitiligo or thyroid disease&#xD;
             taking thyroid replacement are not excluded.&#xD;
&#xD;
          -  Known or suspected impairment of immunologic function including, but not limited to,&#xD;
             clinically significant liver disease; uncontrolled diabetes mellitus; moderate to&#xD;
             severe kidney impairment or post organ transplant subjects.&#xD;
&#xD;
          -  History of malignancy, other than squamous cell or basal cell skin cancer, unless&#xD;
             there has been surgical excision that is considered to have achieved cure.&#xD;
&#xD;
          -  History of coronary heart disease, myocardial infarction, angina, congestive heart&#xD;
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood&#xD;
             pressure, or any other heart condition under the care of a doctor.&#xD;
&#xD;
          -  History of allergies or reactions to eggs, egg products, or gentamycin.&#xD;
&#xD;
          -  Having received any vaccinations or planned vaccinations with a live vaccine within 28&#xD;
             days or a killed vaccine within 14 days prior to or after IMVAMUNE®vaccination.&#xD;
&#xD;
          -  Chronic administration (defined as more than 6 days) of systemic corticosteroids&#xD;
             within 30 days of the first planned vaccination.&#xD;
&#xD;
          -  Use of any investigational or non-registered drug or vaccine other than IMVAMUNE®&#xD;
             within 30 days preceding the first vaccine dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Fujimoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palo Alto Medical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <results_first_submitted>August 4, 2020</results_first_submitted>
  <results_first_submitted_qc>August 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2020</results_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MVA-BN</title>
          <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>MVA-BN</title>
          <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.36" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ELISA Seropositivity Rate</title>
        <description>Seropositivity rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seropositivity is defined as antibody titers ≥ detection limit (50). Percentages based on number of subjects with data available.</description>
        <time_frame>up to Week 7</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-BN</title>
            <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Seropositivity Rate</title>
          <description>Seropositivity rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seropositivity is defined as antibody titers ≥ detection limit (50). Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="20.7" upper_limit="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="84.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA Seroconversion Rate</title>
        <description>Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to the Screening titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
        <time_frame>Week 7</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-BN</title>
            <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Seroconversion Rate</title>
          <description>Seroconversion rate based on Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to the Screening titer for initially seropositive subjects. Percentages based on number of subjects with data available.</description>
          <population>Full Analysis Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="70.8" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMT</title>
        <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
        <time_frame>up to Week 7</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-BN</title>
            <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMT</title>
          <description>Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Titers below the detection limit are included with a value of '1'.</description>
          <population>Full Analysis Set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370.08" lower_limit="166.3" upper_limit="823.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14961.54" lower_limit="11163.8" upper_limit="20051.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE).</description>
        <time_frame>up to 32 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-BN</title>
            <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Incidence, relationship and intensity of any Serious Adverse Event (SAE).</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Related Grade &gt;=3 Adverse Events</title>
        <description>Incidence of any Grade &gt;=3 Adverse Events possibly, probably or definitely related to the trial vaccine</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-BN</title>
            <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
          </group>
        </group_list>
        <measure>
          <title>Related Grade &gt;=3 Adverse Events</title>
          <description>Incidence of any Grade &gt;=3 Adverse Events possibly, probably or definitely related to the trial vaccine</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-serious AEs</title>
        <description>Incidence of non-serious AEs</description>
        <time_frame>within 29 days after any vaccination</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-BN</title>
            <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
          </group>
        </group_list>
        <measure>
          <title>Non-serious AEs</title>
          <description>Incidence of non-serious AEs</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 32 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MVA-BN</title>
          <description>Two s.c. vaccinations with 0.5 ml MVA-BN® vaccine containing 1 x 10E8 TCID50 / dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection site pruritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Lead, Clinical Operations</name_or_title>
      <organization>Bavarian Nordic A/S</organization>
      <phone>+45 3326 ext 8383</phone>
      <email>info@bavarian-nordic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

